Eton Pharmaceuticals, Inc. (ETON) analyst actions
Rating and price-target actions on ETON in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the ETON overview →
2 measured ETON analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Eton Pharmaceuticals Announces Licensing and Initiation of ET-900 Program Evaluating Mecasermin/IGF-1 for Treatment of Infantile and Epileptic Spasms | Press release | -1.51% | -3.99% | |
| Eton Pharmaceuticals Announces Initiation of Clinical Study for Product Candidate ET-700 | Press release | -1.48% | +1.96% |
Keep exploring
More ETON: earnings → · SEC filings → · ETON overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Rockwell Medical, Inc. (RMTI) | 235 | +0.40% | 57% |
| Equillium, Inc. (EQ) | 234 | 0.00% | 51% |
| THERAPIX BIOSCIENCES LTD AMERICAN DEPOSITARY SHARE (TRPX) | 234 | -1.05% | 31% |
| Catalent, Inc. (CTLT) | 232 | +0.10% | 62% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.